Valuation: Madrigal Pharmaceuticals, Inc.

Market Cap 11.73B 10.13B 9.52B 8.66B 16.27B 1,121B 16.54B 112B 43.6B 562B 44.03B 43.07B 1,866B P/E 2026 *
-80.4x
P/E 2027 * 80.6x
Enterprise Value 11.2B 9.68B 9.09B 8.27B 15.55B 1,071B 15.8B 107B 41.65B 536B 42.06B 41.15B 1,783B EV / Sales 2026 *
7.34x
EV / Sales 2027 * 5.03x
Free-Float
94.13%
Yield 2026 *
-
Yield 2027 * -
1 day+0.04%
1 week-0.49%
Current month+8.61%
1 month-5.46%
3 months-5.99%
6 months+9.22%
Current year-12.84%
1 week 494.9
Extreme 494.9
544.49
1 month 447.01
Extreme 447.01
566.18
Current year 416.21
Extreme 416.21
598.79
1 year 351.32
Extreme 351.315
615
3 years 119.76
Extreme 119.7604
615
5 years 52.33
Extreme 52.33
615
10 years 7.79
Extreme 7.79
615
Manager TitleAgeSince
Chief Executive Officer 59 2023-09-07
Director of Finance/CFO 62 2024-03-10
Chief Tech/Sci/R&D Officer 58 2025-04-20
Director TitleAgeSince
Director/Board Member 74 2016-06-30
Director/Board Member 68 2016-08-10
Director/Board Member 64 2019-06-26
Date Insider Type Main position Quantity % Market Cap.
7/20/26 Sell

Chief Executive Officer

-2,500 0.0108%
6/17/26 Free

Director

1,220 0.0053%
2/23/26 Fiscal year

Director

5,000 0.0220%
Change 5-day change 1-year change 3-year change Capi.($)
+0.04%-0.49%+36.67%+192.64% 11.73B
-1.90%+2.85%+61.37%+102.88% 70.07B
-3.21%-4.32%+31.19%+59.75% 52.87B
-2.05%-5.61%-3.14%+454.89% 27.02B
-1.27%-1.57%+46.46%+6.09% 23.61B
+1.05%-0.62%-17.40%-13.36% 23.38B
+3.81%+20.97%+263.48%+552.47% 19.43B
+0.10%+1.40%+38.98%-20.04% 18.75B
-0.95%-3.52%+20.04%+613.01% 15.85B
+1.24%-5.23%+33.19%+138.21% 12.7B
Average -0.31%+1.69%+51.09%+208.65% 27.54B
Weighted average by Cap. -1.04%+0.51%+49.29%+169.14%

Financials

2026 *2027 *
Net sales 1.53B 1.32B 1.24B 1.13B 2.12B 146B 2.15B 14.51B 5.68B 73.09B 5.73B 5.61B 243B 2.14B 1.85B 1.74B 1.58B 2.98B 205B 3.03B 20.4B 7.98B 103B 8.05B 7.88B 341B
Net income -184M -159M -149M -136M -255M -17.58B -259M -1.75B -684M -8.8B -690M -675M -29.26B 200M 173M 162M 148M 278M 19.12B 282M 1.9B 744M 9.58B 751M 735M 31.82B
Net Debt -525M -453M -426M -387M -728M -50.16B -740M -4.99B -1.95B -25.12B -1.97B -1.93B -83.47B -943M -815M -766M -696M -1.31B -90.19B -1.33B -8.97B -3.51B -45.17B -3.54B -3.46B -150B
Logo Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Employees
915
Date Price Change Volume
26-08-14 US$507.56 +0.04% 234,655
26-08-13 US$507.37 -5.38% 277,891
26-08-12 US$536.20 +0.17% 285,551
26-08-11 US$535.27 +3.87% 415,197
26-08-10 US$515.34 +1.04% 283,738
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
507.56USD
Average target price
678.06USD
Spread / Average Target
+33.59%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MDGL Stock